{"cik":1691082,"taxonomy":"us-gaap","tag":"ShareBasedCompensation","label":"Share-based Payment Arrangement, Noncash Expense","description":"Amount of noncash expense for share-based payment arrangement.","entityName":"LB Pharmaceuticals Inc","units":{"USD":[{"start":"2024-01-01","end":"2024-09-30","val":813000,"accn":"0001193125-25-268174","fy":2025,"fp":"Q3","form":"10-Q","filed":"2025-11-06"},{"start":"2024-01-01","end":"2024-12-31","val":3090000,"accn":"0001193125-26-126368","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-26","frame":"CY2024"},{"start":"2025-01-01","end":"2025-03-31","val":634000,"accn":"0001193125-26-219607","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-12","frame":"CY2025Q1"},{"start":"2025-01-01","end":"2025-09-30","val":1850000,"accn":"0001193125-25-268174","fy":2025,"fp":"Q3","form":"10-Q","filed":"2025-11-06"},{"start":"2025-01-01","end":"2025-12-31","val":4191000,"accn":"0001193125-26-126368","fy":2025,"fp":"FY","form":"10-K","filed":"2026-03-26","frame":"CY2025"},{"start":"2026-01-01","end":"2026-03-31","val":2566000,"accn":"0001193125-26-219607","fy":2026,"fp":"Q1","form":"10-Q","filed":"2026-05-12","frame":"CY2026Q1"}]}}